Journal of Oncology / 2009 / Article / Fig 2

Research Article

A Population-Based Clinical Trial of Irinotecan and Carboplatin

Figure 2

Cumulative percent of patients experienced dose-limiting toxicity (DLT) with increasing dose levels of irinotecan and carboplatin (N = 50).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.